Chair’s Address to the Annual General Meeting
21 November 2018
The value the market has placed on the Company reflects the progress made throughout this financial year. In June we filed our first new drug application with the US Food and Drug Administration, a milestone not just for CLINUVEL but for the entire biotechnology industry in Australia. While a number of innovations have come from Australian biotechs, few teams have been able to navigate the pathways necessary to achieve global regulatory filings, or have relied on partnerships with stakeholders and this does not maximise their potential value.